Scientific Advice
This article was originally published in SRA
Executive Summary
EMEA to improve efficiency of procedure
You may also be interested in...
Novartis And The Medicines Company: Five Things To Worry About
The $9.7bn acquisition hinges on the small interfering RNA inclisiran, but an ongoing cardiovascular outcomes trial, manufacturing hurdles, and reimbursement challenges provide subjects for concern.
QUOTED. 12 December 2019. Scott Whitaker
US congressional leaders and medtech industry advocacy group AdvaMed are giving their full-throated endorsement to a US-Mexico-Canada (USMCA) trade agreement announced by the US Trade Representative's Office on 10 December. See what AdvaMed's president and CEO, Scott Whitaker, said about it in a statement here.
Horizon Teprotumumab's US Advisory Cmte. Likely To Focus On Labeling, Not Approval, Questions
FDA seems poised to approve the drug for the orphan eye disease called TED, but remains concerned about labeling for some adverse events.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: